HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits

作者：Saga Ayami; Okura Hanayuki; Soeda Mayumi; Tani Junko; Fumimoto Yuichi; Komoda Hiroshi; Moriyama Mariko; Moriyama Hiroyuki; Yamashita Shizuya; Ichinose Akihiro; Daimon Takashi; Hayakawa Takao; Matsuyama Akifumi^*

来源：Biochemical and Biophysical Research Communications, 2011, 412(1): 50-54.

DOI：10.1016/j.bbrc.2011.07.035

• ADMPC
• WHHL
• HMG-CoA reductase inhibitor
• Pravastatin
• Cholesterol
• Cell therapy

Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.

• 出版日期2011-8-19